Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07327229 is registered in ClinicalTrials.gov with Antengene Biologics Limited as lead sponsor.

NCT NCT07327229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07327229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Antengene Biologics Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 27, 2026
Completion date
April 30, 2029
Enrollment
132 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma